Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Legal Challenge To “ObamaCare” Threatens Generic Biologicals
What should not be lost on pharma/biotech patent attorneys or their clients, amidst all the attention given to the Supreme Court’s review of the “Patient Protection and Affordable Health Care Act” – public law 111-48, is that it contains the … Continue reading
Posted in Follow-On Biologics
Tagged biotechnology law, FDA, Hatch-Waxman, Supreme Court, Warren Woessner
1 Comment
Supreme Court Remands In Myriad Appeal
Today, as predicted by many commentators, the Supreme Court set aside the ruling by the Fed. Cir. that claims to isolated DNA sequences that are the BRCA 1 or 2 gene, or fragments thereof, are patentable subject matter. The Supreme … Continue reading
“Handbook of Quality Procedures Before the EPO”
The ECP, epi and Business Europe have collaborated to produce a downloadable, fifty page guide to practice before the EPO. While not binding on Examiners, it was issued under the authority of the EPO and is a sort of mini-MPEP, … Continue reading
Posted in EP and UK Practice
Tagged biotechnology law, epi, EPO, European patent, intellectual property, ip, Patent Law, patents, Warren Woessner
Leave a comment
PTO To Biotech Examiners – We’ll Get Back To You!
On March 21, 2012, Andrew H Hirschfield, Associate Commissioner for Patent Examination Policy, sent a short memo to the Patent Examining Corps to inform them about the decision in Prometheus v. Mayo. The “preliminary guidance” that was provided included a … Continue reading